Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRP-2 vaccinia virus
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
TRP-2 vaccinia virus is a recombinant viral vector vaccine designed for the treatment of melanoma. It utilizes a vaccinia virus platform to deliver the gene for tyrosinase-related protein 2 (TRP-2), also known as dopachrome tautomerase (DCT), which is a melanocyte differentiation antigen frequently overexpressed in melanoma cells. The vaccine is intended to stimulate the host's immune system to recognize and destroy TRP-2-expressing tumor cells through the activation of CD8+ cytotoxic T lymphocytes and natural killer (NK) cells. Preclinical studies have demonstrated that this approach can effectively treat established tumors in mouse models, such as B16 melanoma, while potentially avoiding the widespread autoimmune depigmentation (vitiligo) often seen with other melanocyte-targeted immunotherapies.
- Other names
- recombinant vaccinia virus encoding trp-2rVV-TRP-2rVV-TRP2rVV-TRP 2vaccinia-trp-2vaccinia-trp2vaccinia-trp 2rVV-DCT
Beyond the preview
Go deeper on TRP-2 vaccinia virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRP-2 vaccinia virus.